Poland
· Delayed Price · Currency is PLN Molecure Statistics
Total Valuation
Molecure has a market cap or net worth of PLN 162.64 million. The enterprise value is 151.68 million.
| Market Cap | 162.64M |
| Enterprise Value | 151.68M |
Important Dates
The last earnings date was Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Molecure has 20.20 million shares outstanding. The number of shares has increased by 20.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 20.20M |
| Shares Change (YoY) | +20.00% |
| Shares Change (QoQ) | +79.01% |
| Owned by Insiders (%) | 3.43% |
| Owned by Institutions (%) | 20.00% |
| Float | 14.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 55.71 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 3.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.85 |
| EV / Sales | 51.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.63 |
Financial Position
The company has a current ratio of 9.82, with a Debt / Equity ratio of 0.07.
| Current Ratio | 9.82 |
| Quick Ratio | 9.70 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | -670.28 |
Financial Efficiency
Return on equity (ROE) is -30.62% and return on invested capital (ROIC) is -18.46%.
| Return on Equity (ROE) | -30.62% |
| Return on Assets (ROA) | -17.87% |
| Return on Invested Capital (ROIC) | -18.46% |
| Return on Capital Employed (ROCE) | -29.74% |
| Revenue Per Employee | 27,801 |
| Profits Per Employee | -297,980 |
| Employee Count | 111 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.27% in the last 52 weeks. The beta is 2.61, so Molecure's price volatility has been higher than the market average.
| Beta (5Y) | 2.61 |
| 52-Week Price Change | -52.27% |
| 50-Day Moving Average | 8.84 |
| 200-Day Moving Average | 11.38 |
| Relative Strength Index (RSI) | 34.75 |
| Average Volume (20 Days) | 22,268 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecure had revenue of PLN 2.92 million and -31.29 million in losses. Loss per share was -1.55.
| Revenue | 2.92M |
| Gross Profit | -489,909 |
| Operating Income | -32.30M |
| Pretax Income | -31.29M |
| Net Income | -31.29M |
| EBITDA | -32.12M |
| EBIT | -32.30M |
| Loss Per Share | -1.55 |
Balance Sheet
The company has 18.19 million in cash and 7.23 million in debt, giving a net cash position of 10.96 million or 0.54 per share.
| Cash & Cash Equivalents | 18.19M |
| Total Debt | 7.23M |
| Net Cash | 10.96M |
| Net Cash Per Share | 0.54 |
| Equity (Book Value) | 103.41M |
| Book Value Per Share | 5.12 |
| Working Capital | 45.14M |
Cash Flow
In the last 12 months, operating cash flow was -56.99 million and capital expenditures -655,332, giving a free cash flow of -57.65 million.
| Operating Cash Flow | -56.99M |
| Capital Expenditures | -655,332 |
| Free Cash Flow | -57.65M |
| FCF Per Share | -2.85 |
Margins
| Gross Margin | -16.78% |
| Operating Margin | -1,106.58% |
| Pretax Margin | -1,071.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Molecure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.00% |
| Shareholder Yield | -20.00% |
| Earnings Yield | -19.24% |
| FCF Yield | -35.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Molecure has an Altman Z-Score of 13.03.
| Altman Z-Score | 13.03 |
| Piotroski F-Score | n/a |